PT Kimia Farma (Persero) Tbk Class B

As of June 30, 2026, PT Kimia Farma (Persero) Tbk Class B carries a market capitalization of 2.34T, placing it among publicly traded companies globally. Its enterprise value stands at 10.00T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, PT Kimia Farma (Persero) Tbk Class B has 5.57B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, PT Kimia Farma (Persero) Tbk Class B maintains a current ratio of 1.03, meaning it holds 1.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 253.84, indicating elevated leverage, while an interest coverage ratio of -0.23 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, PT Kimia Farma (Persero) Tbk Class B recorded an income tax benefit of -786.87M rather than an expense, typically from losses, carryforwards, or the release of a tax provision.

As of the close on October 22, 2026, PT Kimia Farma (Persero) Tbk Class B's stock has declined approximately 39.34% over the past 52 weeks. The 50-day moving average sits at 427.50, while the 200-day moving average is 474.75.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -105.19B, while operating income came in at -105.19B.

As of June 30, 2026, PT Kimia Farma (Persero) Tbk Class B holds 445.47B in cash and equivalents against 7.08T in total debt, resulting in a net debt position of 6.53T. Total book value stands at 1.76T, with working capital of 157.19B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.